Document:

EXHIBIT 10.5

 Exhibit 10.5 
  
 FORM OF 
 SAVINGS INSTITUTE BANK AND TRUST COMPANY 
 CHANGE IN CONTROL AGREEMENT 
  
 This AGREEMENT (“Agreement”) is hereby entered into as of
                    , 2004, by and between Savings Institute Bank and Trust Company (the “Bank”), a federally-chartered
savings bank with its principal offices at 803 Main Street, Willimantic, Connecticut 06226,                     
(“Executive”) and SI Financial Group, Inc. (the “Company”), a federally-chartered corporation and the holding company of the Bank, as guarantor. 
  
 WHEREAS, the Bank recognizes the importance of Executive to the Bank’s operations and wishes to protect his position
with the Bank in the event of a change in control of the Bank or the Company for the period provided for in this Agreement; and 
  
 WHEREAS, Executive and the Board of Directors of the Bank desire to enter into an agreement setting forth the terms and conditions of payments due to
Executive in the event of a change in control and the related rights and obligations of each of the parties. 
  
 NOW, THEREFORE, in consideration of the promises and mutual covenants herein contained, it is hereby agreed as follows: 
  

	1.	Term of Agreement. 

  
 (a) The term of this Agreement shall be (i) the initial term, consisting of the period commencing on the date of this Agreement (the “Effective
Date”) and ending on the                     anniversary of the Effective Date, plus (ii) any and all extensions of the initial term made
pursuant to this Section 1. 
  
 (b) Commencing on the first
anniversary of the Effective Date and continuing each anniversary date thereafter, the Board of Directors of the Bank (the “Board of Directors”) may extend the term of this Agreement for an additional one (1) year period beyond the then
effective expiration date, provided that Executive shall not have given at least sixty (60) days’ written notice of his desire that the term not be extended. 
  
 (c) Notwithstanding anything in this Section to the contrary, this Agreement shall terminate if Executive or the Bank
terminates Executive’s employment prior to a Change in Control. 
  

	2.	Change in Control. 

  
 (a) Upon the occurrence of a Change in Control of the Bank or the Company followed at any time during the term of this Agreement by the termination of
Executive’s employment in accordance with the terms of this Agreement, other than for Just Cause, as defined in Section 2(c) of this Agreement, the provisions of Section 3 of this Agreement 

  

 1 

 
shall apply. Upon the occurrence of a Change in Control, Executive shall have the right to elect to voluntarily terminate his employment at any time during
the term of this Agreement following an event constituting “Good Reason.” 
  
 “Good Reason” means, unless Executive has consented in writing thereto, the occurrence following a Change in Control, of any of the following: 
  

	 	(i)	the assignment to Executive of any duties materially inconsistent with Executive’s position, including any material change in status, title, authority, duties or
responsibilities or any other action that results in a material diminution in such status, title, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and that is
remedied by the Bank or Executive’s employer reasonably promptly after receipt of notice thereof given by the Executive; 

  

	 	(ii)	a reduction by the Bank or Executive’s employer of the Executive’s base salary in effect immediately prior to the Change in Control; 

  

	 	(iii)	the relocation of the Executive’s office to a location more than
                     miles from its location as of the date of this Agreement; 

  

	 	(iv)	the taking of any action by the Bank or any of its affiliates or successors that would materially adversely affect the Executive’s overall compensation and benefits package,
unless such changes to the compensation and benefits package are made on a non-discriminatory basis to all employees; or 

  

	 	(v)	the failure of the Bank or the affiliate of the Bank by which Executive is employed, or any affiliate that directly or indirectly owns or controls any affiliate by which Executive
is employed, to obtain the assumption in writing of the Bank’s obligation to perform this Agreement by any successor to all or substantially all of the assets of the Bank or such affiliate within thirty (30) days after a reorganization, merger,
consolidation, sale or other disposition of assets of the Bank or such affiliate. 

  
 (b) For purposes of this Agreement, a “Change in Control” shall be deemed to occur on the earliest of any of the following events: 

 
 (i) Merger: The Company merges into or consolidates with another
corporation, or merges another corporation into the Company, and as a result less than a majority of the combined voting power of the resulting corporation immediately after the merger or consolidation is held by persons who were stockholders of the
Company immediately before the merger or consolidation. 
  

 2 

 (ii) Acquisition of Significant Share Ownership: The Company files, or is required to file, a
report on Schedule 13D or another form or schedule (other than Schedule 13G) required under Sections 13(d) or 14(d) of the Securities Exchange Act of 1934, if the schedule discloses that the filing person or persons acting in concert has or have
become the beneficial owner of 25% or more of a class of the Company’s voting securities, but this clause (b) shall not apply to beneficial ownership of Company voting shares held in a fiduciary capacity by an entity of which the Company
directly or indirectly beneficially owns 50% or more of its outstanding voting securities. 
  
 (iii) Change in Board Composition: During any period of two consecutive years, individuals who constitute the Company’s Board of Directors at the beginning of the two-year period cease for any reason to
constitute at least a majority of the Company’s Board of Directors; provided, however, that for purposes of this clause (iii), each director who is first elected by the board (or first nominated by the board for election by the stockholders) by
a vote of at least two-thirds (2/3) of the directors who were directors at the beginning of the two-year period shall be deemed to have also been a director at the beginning of such period; or 
  
 (iv) Sale of Assets: The Company sells to a third party all or
substantially all of its assets. 
  
 Notwithstanding anything in
this Agreement to the contrary, in no event shall the conversion of SI Bancorp, MHC from mutual to stock form (including without limitation, through the formation of a stock holding company) constitute a “Change in Control” for purposes of
this Agreement. 
  
 (c) Executive shall not have the right to
receive termination benefits pursuant to Section 3 hereof upon termination for Just Cause. The term “Just Cause” shall mean termination because of Executive’s personal dishonesty, incompetence, willful misconduct, any breach of
fiduciary duty involving personal profit, intentional failure to perform stated duties, willful violation of any law, rule, regulation (other than traffic violations or similar offenses), final cease and desist order, or any material breach of any
provision of this Agreement. Notwithstanding the foregoing, Executive shall not be deemed to have been terminated for Just Cause unless and until there shall have been delivered to him a copy of a resolution duly adopted by the affirmative vote of a
majority of the entire membership of the Board of Directors at a meeting of the Board of Directors called and held for that purpose (after reasonable notice to Executive and an opportunity for him, together with counsel, to be heard before the Board
of Directors), finding that in the good faith opinion of the Board of Directors, Executive was guilty of conduct justifying termination for Just Cause and specifying the particulars thereof in detail. Executive shall not have the right to receive
compensation or other benefits for any period after termination for Just Cause. During the period beginning on the date of the Notice of Termination for Just Cause pursuant to Section 4 hereof through the Date of Termination, stock options granted
to Executive under any stock option plan shall not be exercisable nor shall any unvested stock awards granted to Executive under any stock benefit plan of the Bank, the Company or any 

  

 3 

 
subsidiary or affiliate thereof, vest. At the Date of Termination, such stock options and any such unvested stock awards shall become null and void and shall
not be exercisable by or delivered to Executive at any time subsequent to such termination for Just Cause. 
  

	3.	Termination Benefits. 

  
 (a) If Executive’s employment is voluntarily (in accordance with Section 2(a) of this Agreement) or involuntarily terminated within
                     years of a Change in Control, Executive shall receive: 
  

	 	(i)	a lump sum cash payment equal to                     
(            ) times the Executive’s “base amount,” within the meaning of Section 280G(b)(3) of the Internal Revenue Code of 1986, as amended (the “Code”).
Such payment shall be made not later than five (5) days following Executive’s termination of employment under this Section 3. 

  

	 	(ii)	Continued benefit coverage under all Bank health and welfare plans which Executive participated in as of the date of the Change in Control (collectively, the “Employee Benefit
Plans”) for a period of                      (            ) months
following Executive’s termination of employment. Said coverage shall be provided under the same terms and conditions in effect on the date of Executive’s termination of employment. Solely for purposes of benefits continuation under the
Employee Benefit Plans, Executive shall be deemed to be an active employee. To the extent that benefits required under this Section 3(a) cannot be provided under the terms of any Employee Benefit Plan, the Bank shall enter into alternative
arrangements that will provide Executive with comparable benefits. 

  
 (b) Notwithstanding the preceding provisions of this Section 3, in no event shall the aggregate payments or benefits to be made or afforded to Executive under said paragraphs (the “Termination Benefits”)
constitute an “excess parachute payment” under Section 280G of the Code or any successor thereto, and to avoid such a result, Termination Benefits will be reduced, if necessary, to an amount (the “Non-Triggering Amount”), the
value of which is one dollar ($1.00) less than an amount equal to three (3) times Executive’s “base amount,” as determined in accordance with said Section 280G. The allocation of the reduction required hereby among the Termination
Benefits provided by this Section 3 shall be determined by Executive. 
  

	4.	Notice of Termination. 

  
 (a) Any purported termination by the Bank or by Executive shall be communicated by Notice of Termination to the other party hereto. For purposes of this
Agreement, a “Notice of Termination” shall mean a written notice which shall indicate the specific termination provision in this Agreement relied upon and shall set forth in detail the facts and circumstances claimed to provide a basis for
termination of Executive’s employment under the provision so indicated. 
  

 4 

 (b) “Date of Termination” shall mean the date specified in the Notice of Termination (which, in
the case of a termination for Just Cause, shall not be less than thirty (30) days from the date such Notice of Termination is given). 
  

	5.	Source of Payments. 

  
 All payments provided in this Agreement shall be timely paid in cash or check from the general funds of the Bank. The Company, however, unconditionally
guarantees payment and provision of all amounts and benefits due hereunder to Executive and, if such amounts and benefits due from the Bank are not timely paid or provided by the Bank, such amounts and benefits shall be paid or provided by the
Company.  
  

	6.	Effect on Prior Agreements and Existing Benefit Plans. 

  
 This Agreement contains the entire understanding between the parties hereto and supersedes any prior agreement between the Bank and Executive, except that
this Agreement shall not affect or operate to reduce any benefit or compensation inuring to Executive of a kind elsewhere provided. No provision of this Agreement shall be interpreted to mean that Executive is subject to receiving fewer benefits
than those available to him without reference to this Agreement. Nothing in this Agreement shall confer upon Executive the right to continue in the employ of the Bank or shall impose on the Bank any obligation to employ or retain Executive in its
employ for any period. 
  

	7.	No Attachment. 

  
 (a) Except as required by law, no right to receive payments under this Agreement shall be subject to anticipation, commutation, alienation, sale,
assignment, encumbrance, charge, pledge, or hypothecation or to execution, attachment, levy or similar process or assignment by operation of law, and any attempt, voluntary or involuntary, to affect any such action shall be null, void and of no
effect. 
  
 (b) This Agreement shall be binding upon, and inure to
the benefit of, Executive, the Bank and their respective successors and assigns. 
  

	8.	Modification and Waiver. 

  
 (a) This Agreement may not be modified or amended except by an instrument in writing signed by the parties hereto. 
  
 (b) No term or condition of this Agreement shall be deemed to have been
waived, nor shall there be any estoppel against the enforcement of any provision of this Agreement, except by written instrument of the party charged with such waiver or estoppel. No such written waiver shall be deemed a continuing waiver unless
specifically stated therein, and each such waiver shall operate only as to the specific term or condition waived and shall not constitute a waiver of such term or condition for the future or as to any act other than that specifically waived.

  

 5 

	9.	Severability. 

  
 If, for any reason, any provision of this Agreement, or any part of any provision, is held invalid, such invalidity shall not affect any other provision
of this Agreement or any part of such provision not held so invalid, and each such other provision and part thereof shall to the full extent consistent with law continue in full force and effect. 
  

	10.	Headings for Reference Only. 

  
 The headings of sections and paragraphs herein are included solely for convenience of reference and shall not control the meaning or interpretation of any
of the provisions of this Agreement. In addition, references herein to the masculine shall apply to both the masculine and the feminine. 
  

	11.	Governing Law. 

  
 Except to the extent preempted by federal law, the validity, interpretation, performance, and enforcement of this Agreement shall be governed by the laws
of the State of Connecticut, without regard to principles of conflicts of law of that State. 
  

	12.	Arbitration. 

  
 Any dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by arbitration, conducted before a panel of
three arbitrators sitting in a location selected by Executive within fifty (50) miles from the location of the Bank, in accordance with the rules of the American Arbitration Bank then in effect. Judgment may be entered on the arbitrator’s award
in any court having jurisdiction; provided, however, that Executive shall be entitled to seek specific performance of his right to be paid until the Date of Termination during the pendency of any dispute or controversy arising under or in connection
with this Agreement. 
  

	13.	Payment of Legal Fees. 

  
 All reasonable legal fees paid or incurred by Executive pursuant to any dispute or question of interpretation relating to this Agreement shall be paid or
reimbursed by the Bank, only if Executive is successful pursuant to a legal judgment, arbitration or settlement. 
  

	14.	Indemnification. 

  
 The Company or the Bank shall provide Executive (including his heirs, executors and administrators) with coverage under a standard directors’ and
officers’ liability insurance policy at its expense and shall indemnify Executive (and his heirs, executors and administrators) to the fullest extent permitted under applicable law against all expenses and liabilities reasonably incurred by him
in connection with or arising out of any action, suit or proceeding in which he may be involved by reason of his having been a director or officer of the Company or the Bank 

  

 6 

 
(whether or not he continues to be a director or officer at the time of incurring such expenses or liabilities), such expenses and liabilities to include,
but not be limited to, judgments, court costs, attorneys’ fees and the cost of reasonable settlements. 
  

	15.	Successors to the Bank and the Company. 

  
 The Bank and the Company shall require any successor or assignee, whether direct or indirect, by purchase, merger, consolidation or otherwise, to all or
substantially all of the business or assets of the Bank or the Company, expressly and unconditionally to assume and agree to perform the Bank’s and the Company’s obligations under this Agreement, in the same manner and to the same extent
that the Bank and the Company would be required to perform if no such succession or assignment had taken place. 
  
  16. Required Provisions. In the event any of the foregoing provisions of this Section 16 are in conflict with the terms of this Agreement, this Section 16 shall
prevail. 
   

	 	a.	The Bank’s board of directors may terminate Executive’s employment at any time, but any termination by the Bank, other than Termination for Cause, shall not prejudice
Executive’s right to compensation or other benefits under this Agreement. Executive shall not have the right to receive compensation or other benefits for any period after Termination for Cause. 

   

	 	b.	If Executive is suspended from office and/or temporarily prohibited from participating in the conduct of the Bank’s affairs by a notice served under Section 8(e)(3) or 8(g)(1)
of the Federal Deposit Insurance Act, 12 U.S.C. §1818(e)(3) or (g)(1); the Bank’s obligations under this contract shall be suspended as of the date of service, unless stayed by appropriate proceedings. If the charges in the notice are
dismissed, the Bank may in its discretion: (i) pay Executive all or part of the compensation withheld while their contract obligations were suspended; and (ii) reinstate (in whole or in part) any of the obligations which were suspended.

   

	 	c.	If Executive is removed and/or permanently prohibited from participating in the conduct of the Bank’s affairs by an order issued under Section 8(e)(4) or 8(g)(1) of the Federal
Deposit Insurance Act, 12 U.S.C. §1818(e)(4) or (g)(1), all obligations of the Bank uder this contract shall terminate as of the effective date of the order, but vested rights of the contracting parties shall not be affected.

   

	 	d.	If the Bank is in default as defined in Section 3(x)(1) of the Federal Deposit Insurance Act, 12 U.S.C. §1813(x)(1) all obligations of the Bank under this contract shall
terminate as of the date of default, but this paragraph shall not affect any vested rights of the contracting parties. 

   

	 	e.	All obligations under this contract shall be terminated, except to the extent determined that continuation of the contract is necessary for the continued operation of the Bank: (i)
by the Director of the OTS (or his designee), at the time the FDIC or the Resolution Trust Corporation, at the time the FDIC enters into an agreement to provide assistance to or on behalf of the Bank under the authority contained in Section 13(c) of
the Federal Deposit Insurance Act, 12 U.S.C. §1823(c); or (ii) by the Director of the OTS (or his designee) at the time the Director (or his designee) approves a supervisory merger to resolve problems related to the operations of the Bank or
when the Bank is determined by the Director to be in an unsafe or unsound condition. Any rights of the parties that have already vested, however, shall not be affected by such action. 

   

	 	f.	Any payments made to employees Executive pursuant to this Agreement, or otherwise, are subject to and conditioned upon their compliance with 12 U.S.C. §1828(k) and FDIC
regulation 12 C.F.R. Part 359, Golden Parachute and Indemnification Payments. 

   

 7 

 SIGNATURES 
  

IN WITNESS WHEREOF, Savings Institute Bank and Trust Company and SI Financial Group, Inc. have caused this Agreement to be executed and their seals to
be affixed hereunto by their duly authorized officers, and Executive has signed this Agreement, on the              day of
                    , 200            . 
  

									
	 ATTEST:
	 	 	 	SAVINGS INSTITUTE BANK AND TRUST COMPANY
					
	 	 	 	 	 	 	By:	 	 
	Corporate Secretary	 	 	 	        For the Entire Board of Directors
			
	 ATTEST:
	 	 	 	 SI FINANCIAL GROUP, INC.
 (Guarantor)

					
	 	 	 	 	 	 	By:	 	 
	Corporate Secretary	 	 	 	        For the Entire Board of Directors
			
	[SEAL]	 	 	 	 
			
	WITNESS:	 	 	 	EXECUTIVE
				
	 	 	 	 	 	 	 
	Corporate Secretary	 	 	 	 	 	 

  

 8Amendment No.1 to the Collaboration Agreement

 Exhibit 10.1 
  
 Execution Copy 
  
 AMENDMENT NO. 1 TO 
  
 COLLABORATION AGREEMENT 
  
 This Amendment No. 1 (“Amendment No. 1”) to the Collaboration Agreement dated as of April 14, 2002 by and between Adolor Corporation, a Delaware corporation, (“Adolor”) and Glaxo Group Limited, a United Kingdom
corporation (“GSK”) (the “Collaboration Agreement”) is entered into as of the 22nd day of June, 2004 by and between Adolor and GSK and shall be effective as of June 24, 2003. 
  
 RECITALS 
  
 WHEREAS the Parties have been collaborating in the Development of alvimopan pursuant to the terms of the Collaboration
Agreement; and 
  
 WHEREAS, the Parties have determined to amend
Article 3 “Governance of Development and Commercialization of Products” in the manner set forth below. 
  
 NOW THEREFORE, intending to be legally bound, the Parties agree as follows: 
  
 1. Capitalized terms used in this Amendment No.1 shall have the same meanings as in the Collaboration Agreement, unless otherwise defined herein. 
  
 2. Section 1.79 of the Collaboration Agreement defining the term “Joint Development
Committee” shall be deleted in its entirety and replaced with the following Section 1.79. 
  

	 	“1.79	“Asset Management Team” shall have the meaning set forth in Section 3.2.1.” 

  
 Every place that the term “Joint Development Committee” appears throughout the Collaboration Agreement shall be replaced by the
term “Asset Management Team.” 
  
 3. Section 1.81 of the Collaboration
Agreement defining the term “Joint Marketing Committee” shall be deleted in its entirety and replaced with the following Section 1.81: 
  

	 	“1.81	“Joint U.S. Marketing Team” shall have the meaning set forth in Section 3.3.1.” 

  
 Every place that the term “Joint Marketing Committee” appears throughout the Collaboration Agreement shall be replaced by the term
“Joint U.S. Marketing Team.” 

 4. Section 1.82 of the Collaboration Agreement defining the term “Joint Supply Committee” shall be deleted in
its entirety and every place that the term “Joint Supply Committee” appears throughout the Collaboration Agreement shall be replaced by the term “Asset Management Team.” 
  
 5. Section 3.2.1, of the Collaboration Agreement shall be deleted in its entirety and
replaced with the following Section 3.2.1. 
  

	 	“3.2	Asset Management Team 

  

	 	3.2.1	Members; Officers; Subteams . The Parties have established an Asset Management Team (the “Asset Management Team”), to which GSK and Adolor shall designate an
equal number of representatives, up to a maximum total of twenty (20) members on such Asset Management Team. Each of GSK and Adolor may replace any or all of its representatives on the Asset Management Team at any time upon written notice to the
other Party. Such representatives shall include individuals who have clinical trial and regulatory experience, expertise in pharmaceutical drug Development, Commercialization and manufacturing and supply of drugs. A Party may designate a substitute
to temporarily attend and perform the functions of such Party’s designee at any meeting of the Asset Management Team. GSK and Adolor each may, on advance notice to the other Party, invite non-member representatives of such Party to attend
meetings of the Asset Management Team. The Asset Management Team shall be chaired on an annual rotating basis by a representative of either Adolor or GSK, as applicable, with Adolor providing the chairperson for the annual term beginning July 1,
2003 through June 30, 2004. The chairperson shall appoint a secretary of the Asset Management Team, who shall be a representative of the other Party and who shall serve for the same annual term as such chairperson. The Asset Management Team shall
operate as a joint team for the Development and coordination of the Commercialization of Compound. In carrying out its responsibilities as set forth in Section 3.2.2, the Asset Management Team shall have the authority but not the obligation to
establish one or more subteams with representation from each of GSK and Adolor to take on and coordinate activities as identified by the Asset Management Team (each a “Subteam” together, the “Subteams”). By way of example and not
limitation, Subteams may be designated for: commercial; supply/chemistry and manufacturing; clinical and statistical; nonclinical; and regulatory. For each Subteam established, the Asset Management Team shall have the authority to: determine the
disciplines that need to be represented from each of GSK and Adolor, delegate activities to 

  

 2 

 the Subteam, approve the charter for the Subteam, set up procedural mechanisms for the Subteam to
interact with the Asset Management Team, and disband the Subteam. Notwithstanding any such delegation of activities to a Subteam, the Asset Management Team shall be fully responsible for all of the responsibilities set forth in Section 3.2.2,
including all activities delegated to the Subteams.” 
  
 6. Section 3.2.2(f)
shall be revised to delete from the first line of that Section the following: “At each meeting of the Joint Development Committee,” and to replace that language with the following: “Quarterly the Asset Management Team shall”

  
 7. Section 3.2.2 shall be further amended to delete the current Section
3.2.2(h) and to add the following provisions: 
  
 “(h)
Coordinate Development and Commercialization of the Collaboration Products in the ROW with the Development and Commercialization of the Collaboration Products in the United States; 
  
 (i) Coordinate life cycle management of, and intellectual property protection for, the Collaboration Products in the United
States and the ROW; 
  
 (j) Manage and oversee the activities in
relation to manufacture and supply of API Compound and Collaboration Products for use in Development and Commercialization and establish procedures and protocols for testing API Compound and Collaboration Products to ensure that such API Compound
and Collaboration Products comply with the specifications (the “Testing Protocol”). The Parties will utilize such Testing Protocol with respect to API Compound and Collaboration Product that they may receive from Product Suppliers
to ensure that such API Compound or Collaboration Product meets specifications; 
  
 (k) Recommend and coordinate necessary adjustments to the manufacturing schedule to ensure it is meeting the needs for all Collaboration Products; 
  
 (l) Coordinate allocation of API Compound in the event of a shortage between the United States and the ROW, it being
understood that, in the event of a shortage, allocation of API Compound shall be as follows: (i) requirements for use in POI Products for Commercialization in the United States shall have first priority; (ii) requirements for use in POI Products for
Commercialization in the ROW shall have second priority; (iii) requirements for use in Collaboration Products (other than POI Product) in the United States shall have third priority; (iv) requirements for use in Collaboration Products (other than
POI Product) for Commercialization in 
  

 3 

 the ROW shall have fourth priority; and (v) requirements for use in all other Products containing API
Compound shall have fifth priority. The foregoing priority allocations may be revised by the Asset Management Team based on the relative commercial value of such Collaboration Products; 
  
 (m) Review the quality of the manufacture of the Collaboration Products, reviewing as appropriate reports of the
manufacturers of API Compound and Collaboration Products and reports as to the quality of any packaging that bears the relevant trademarks or housemarks of the Parties (as owned by or licensed to the relevant Party under Section 2.4) as prescribed
by this Agreement; 
  
 (n) Recommend and implement optimal
inventory levels and safety stock targets; 
  
 (o) Set
improvement targets and monitor performance against these targets for cost, yield, delivery and other appropriate measures; 
  
 (p) Establish guidelines to facilitate improved efficiencies and compliance with current Good Manufacturing Practices by Product Suppliers; and

  
 (q) Have such other responsibilities as may be assigned to
the Asset Management Team pursuant to this Agreement or as may be mutually agreed upon by the Parties from time to time.” 
  
 8. Section 3.2.5 shall be amended to add the following sentence as the last sentence of Section 3.2.5 : “Notwithstanding the foregoing any matter relating to supply
of API Compound or any Collaboration Product assigned for decision-making to a Party in Article 10 or in the further agreements between the Parties contemplated thereby shall not be subject to referral to the Joint Steering Committee.”

  
 9. Section 3.4, including Section 3.4.1, 3.4.2, 3.4.3 and 3.4.4, shall be
deleted in its entirety. 
  
 10. The term “committee” throughout the
Collaboration Agreement shall also be read to refer to the “team” as and if the context requires. 
  
 11. Except as specifically set forth above, the Collaboration Agreement remains in full force and effect as originally executed. 
  

 4 

 IN WITNESS WHEREOF, the Parties have executed this Amendment No.1 as of this 22nd day of June 2004. 
  

							
	 ADOLOR CORPORATION
	 	 GLAXO GROUP LIMITED

				
	 By:
	 	 /s/ Bruce A. Peacock

	 	 By:
	 	 /s/ Leo Nuttall

	 Name:
	 	 Bruce A. Peacock
	 	 Name:
	 	 Leo Nuttall

	 Title:
	 	 President and Chief Executive Officer
	 	 Title:
	 	 Corporate Director

  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]